Showing results (51-60 of 132) with videos related to
Sort By:
Pageof 14
The Journal of Antimicrobial Chemotherapy|September 21, 2006
Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patientsJennifer Ford, Marta Boffito, Desmond Maitland, et al.The Journal of Antimicrobial Chemotherapy|February 22, 2005
Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice dailyMarta Boffito, Desmond Maitland, Laura Dickinson, et al.Antiviral Therapy|January 24, 2012
Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjectsAkil Jackson, Graeme Moyle, Laura Dickinson, et al.Antimicrobial Agents and Chemotherapy|June 25, 2004
Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patientsJennifer Ford, Marta Boffito, Adrian Wildfire, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|October 16, 2004
Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patientsMarta Boffito, Laura Dickinson, Andrew Hill, et al.HIV Medicine|February 18, 2026
The effect of Biktarvy (B/F/TAF) on whole-body insulin sensitivity, lipid and endocrine profile in healthy volunteersJoseph Heskin, Roya Movahedi, Sujin Kang, et al.The Journal of Antimicrobial Chemotherapy|March 12, 2011
Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteersAkil Jackson, Antonio D'Avolio, Victoria Watson, et al.The Journal of Antimicrobial Chemotherapy|January 30, 2004
Surveillance of HIV antiretroviral drug resistance in treated individuals in England: 1998-2000Paul Scott, Eve Arnold, Barry Evans, et al.AIDS Research and Human Retroviruses|August 17, 2006
Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir dosesMarta Boffito, Desmond Maitland, Laura Dickinson, et al.Vaccine|December 3, 2014
Therapeutic immunisation plus cytokine and hormone therapy improves CD4 T-cell counts, restores anti-HIV-1 responses and reduces immune activation in treated chronic HIV-1 infectionAnna Herasimtschuk, Jocelyn Downey, Mark Nelson, et al.Pageof 14